Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CLTA pseudogene 2 (CLTAP2) is a non-functional copy of the Clathrin light chain A (CLTA) gene—a type of pseudogene found in the human genome. Pseudogenes are generally regarded as genomic DNA sequences similar to normal genes but are non-functional; they lack the ability to code for proteins due to disabling mutations or premature stop codons. CLTAP2 does not encode a functional protein, and like other pseudogenes, it may potentially have regulatory roles at the RNA level, such as acting as a decoy for microRNAs or participating in competing endogenous RNA (ceRNA) networks; however, there is no specific functional evidence for this particular pseudogene. Pseudogenes overall are not considered drug targets, and CLTAP2 is not associated with any known drugs, disease pathways, or direct roles in human pathology.
No established mechanism; pseudogene-derived transcripts may act as RNA sponges or competing endogenous RNAs for microRNA binding, in general.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clathrin light chain A pseudogene 2 (CLTAP2).